Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive
Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.
38/435 Publicaciones
-
Toward non-invasive assessment strategies in autoimmune hepatitis.
-
Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.
-
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
-
Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.
-
Screening studies of transient elastography and FibroTest in the general population - Authors' reply.
-
Screening studies of transient elastography and FibroTest in the general population.
-
Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?
-
Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.
-
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
-
Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?
-
FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.
-
Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.
-
The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.
-
Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation.
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Combination of fibrosis tests: sequential or synchronous?
-
Liver biopsy: the best standard...when everything else fails.
-
The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests".
-
Clinical applicability of non-invasive markers for liver fibrosis in chronic hepatitis C (Letter)
-
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.
-
FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.
-
Implementing non-invasive markers for liver fibrosis in clinical practice.
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
-
The use of enzyme results for liver fibrosis evaluation neccessitates standardization.
-
Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?
-
External validation of FibroIndex.
-
Diagnostic value of FibroTest with normal serum aminotransferases.
-
FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.
-
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di Martino V, Thabut D, Moussalli J, Benhamou Y
Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.